利伐沙班预防血栓的研究进展

Rivaroxaban in Prevention of Thrombosis

以利伐沙班为代表的直接口服抗凝药逐渐在心血管疾病、骨外科及急重症等诸多领域取得不错的疗效成果。和传统口服抗凝药相比,利伐沙班有其特有的优势,如稳定可依赖的药代动力学、不需频繁的实验室监测等。除应用于非瓣膜性心房颤动的卒中预防以及静脉血栓栓塞症的二级预防,利伐沙班对于其他疾病相关性血栓及栓塞事件的预防作用还有待于更多循证医学证据支持。根据血栓的形成机制的不同,现从静脉系统、动脉系统以及心腔内血栓三个部分论述利伐沙班作为预防用药的研究进展。

Direct oral anticoagulants,represented by rivaroxaban,have been gradually achieved remarkable results in numerous areas such as cardiovascular diseases,major orthopaedic surgery and emerging diseases.Compared with classic oral anticoagulants,rivaroxaban has its unique advantages,such as stable and reliable pharmacokinetics with no need for frequent laboratory monitoring.Besides for stroke prevention in patients with non-valvular atrial fibrillation and for secondary prevention of venous thromboembolism,more evidence is required to explore the value of rivaroxaban in the prevention of other thromboembolic events.According to the different mechanisms of thrombosis,the paper reviews the research progress of rivaroxaban as a prophylactic agent in three sections:venous thrombosis,arterial thrombosis and intracardiac thrombosis.